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Abstract Prognostic multigene expression assays have be-
come widely available to provide additional information to
standard clinical parameters and to support clinicians in treat-
ment decisions. In this study, we analyzed the impact of
variations in tissue handling on the diagnostic EndoPredict
test results. EndoPredict is a quantitative reverse transcription
PCR assay conducted on RNA from formalin-fixed, paraffin-
embedded (FFPE) tissue that predicts the likelihood of distant
recurrence in patients with ER-positive/HER2-negative breast
cancer. In this study, we performed a total of 138 EndoPredict
assays to study the effects of preanalytical variables such as
time to fixation, fixation time, tumor cell content, and section
storage time on the EndoPredict test results. A time to fixation
of up to 12 h and fixation of up to 5 days did not affect the
results of the gene expression test. Paired samples of FFPE
sections with tumor cell content ranging from 15 to 95 % and
tumor-enriched samples showed a correlation coefficient of
0.97. Test results of tissue sections that have been stored for
12 months at +4 or +20 °C showed a correlation of 0.99 when
compared to results of nonstored sections. In conclusion,
preanalytical tissue handling is not a critical factor for diag-
nostic gene expression analysis with the EndoPredict assay.
The test can therefore be easily integrated into the standard
workflow of molecular pathology.
Keywords Breast cancer . Preanalytical . EndoPredict .
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Introduction
In recent years, multigene expression assays for breast cancer
prognosis have become widely available to provide additional
information to standard clinical parameters and histopatholog-
ical techniques supporting clinicians in treatment decisions
[1–4]. RNA from formalin-fixed, paraffin-embedded (FFPE)
tissues is commonly used as sample material, since fresh-
frozen tissue is difficult to handle in a routine clinical care
environment. Although tissue processing can be partially au-
tomated using robotic instrumentation, the current practice of
sample collection, handling, and storage is not entirely stan-
dardized. This can potentially impact also gene expression
assays based on RNA from FFPE tissue. Numerous studies
have demonstrated that mRNA from FFPE tissues can be
reliably quantified by quantitative RT-PCR [5, 6]. However,
several studies already showed that preanalytical variables
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during tissue processing can have an influence on the quality
of the RNA and thus potentially influence test results of
multigene assays [7, 8]. Relevant factors include the time to
fixation (TTF), the fixation time (FT), and the tissue section
storage time (SST). Results from recent studies have indicated
that the tumor cell content (TCC) or rather the amount of
tumor-adjacent normal breast tissue can also have an effect
on the performance of RNA markers [9, 10]. So far, little is
known about the impact of these variables on the results of
gene expression-based cancer prognosis tests, including
EndoPredict.
The EndoPredict test is an RNA-based reverse transcrip-
tion PCR assay that predicts the likelihood of disease recur-
rence in women with estrogen receptor positive (ER+) and
human epidermal growth factor receptor 2 negative (HER2−)
breast cancer [1]. The assay analyzes the expression level of
eight cancer-related genes and four reference/control genes
within the breast tumor to determine an EndoPredict score in
the range of 0 to 15. Each score corresponds to a specific
likelihood of breast cancer recurrence within 10 years after the
initial diagnosis. Based on the calculated EP score, the patient
is categorized as low (0 to <5) or high risk (5 to 15) for distant
recurrence under endocrine therapy. By combining the EP
score with the clinical risk factors tumor size and nodal status,
a hybrid molecular and clinical risk score (EPclin) is defined.
The EPclin score outperforms all conventional clinicopatho-
logical risk parameters (including Ki-67, quantitative ER, and
grading [1]) and improves clinical guideline-based risk clas-
sification of patients with ER+/HER2− breast cancer [11].
EndoPredict was validated in patients from two independent
phase III trials (ABCSG-6 n=378, ABCSG-8 n=1324)
resulting in a level of evidence of I according to Simon et al.
[12]. The test was analytically validated [13] and enables
reliable decentral gene expression analysis in local molecular
pathological laboratories [14]. The impact of variations in
tissue handling, however, has not been studied so far.
Here, we performed a total of 138 EndoPredict assays to
study the effects of preanalytical variations such as TTF, FT,
TCC, and SST on the results of the EndoPredict breast cancer
prognosis test.
Materials and methods
Sample material and tissue handling
An overview on the different preanalytical variables is shown
in Fig. 1. For TTF studies, one breast tumor was dissected into
nine pieces of similar size immediately after surgery. Each
piece of tissue was transferred into a separate sterile Petri dish
which was closed with a loose fitting lid. The remaining tumor
material was used for standard histopathological diagnostics.
Two tumor pieces in sterile Petri dishes were stored at 4 °C,
four pieces at room temperature (20 °C), and three pieces at
37 °C without use of buffers, solutions, or stabilization re-
agents. After 10 min and after 1 h, respectively, one tumor
piece from 20 and 37 °C was transferred from the Petri dishes
into 10 % neutral buffered formalin. After 12 h, three further
pieces, each from 4, 20, and 37 °C storage, were fixed in
formalin. Remaining tissue pieces at 4 and 20 °C were fixed
after 24 h. All specimens were fixed for ∼20 h in 10 % neutral
buffered formalin (ratio fixative/tissue 20:1 or higher) follow-
ed by automated tissue processing and paraffin embedding.
Two 10-μm FFPE tissue sections of each tumor piece were
used for RNA isolation and analysis by EndoPredict.
In order to study the effect of the FT, another breast tumor
was cut after resection into six pieces of similar size. All
pieces were immediately transferred into 10 % neutral buff-
ered formalin with a ratio of fixative to tissue of 20:1 or higher.
Fixation was performed for 1 h, 6 h, 20 h, 2 days, 5 days, or
10 days. After each time point, samples were processed using
an automated tissue processor (Leica, Wetzlar, Germany)
followed by paraffin embedding. EP scores were determined
after RNA isolation using two 10-μm tissue sections per
tumor piece.
FFPE tissue samples for TCC studies were taken from 39
patients with ER+/HER2− breast cancer. The clinical data of
all patients are summarized in Table 1. Five consecutive FFPE
tissue sections were used for this study. One 3-μm and three
5-μm sections were mounted on glass. The 3-μm section on
the glass slide was stained by H&E, and the tumor area
(invasive tumor area, including interposed tumor-related stro-
ma and ductal carcinoma in situ (DCIS)) was marked with ink
by a pathologist on the glass slide. Afterward, the tumor
content was assessed. Tumor content was defined as the
estimated area of marked section in relation to residual tissue,
whereas adipose tissue was not considered as residual tissue.
In this study, the tumor content ranged from 15 to 95 %. The
corresponding tumor area was copied onto the three consecu-
tive unstained 5-μM sections on glass slides. The marked
tumor areas from the three sections of the same tumor were
scraped and combined into a sterile tube which contained lysis
buffer for RNA isolation. These combined sections represent
the tumor-enriched sample with a TCC of approximately
100 % (manually microdissected sections). In addition, a
whole 10-μm section of each tumor was placed in a tube
(whole section). EP and EPclin scores of whole tissue sections
were compared to EP and EPclin scores of tumor-enriched,
microdissected sections. EPclin scores were only calculated
and compared for 38 tumor samples, since the nodal status of
one patient was not available.
Three 10-μm sections of 10 ER+/HER2− breast tumors
were used to study the impact of the tissue SST on the
EndoPredict test results. At the beginning of the study, RNA
was isolated from a single section of each tumor, and the EP
scores were determined. The remaining two tissue sections of
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each tumor were either stored for 12 months at 4 °C or for
12 months at 20 °C. Afterward, the RNAwas isolated, and the
EP scores were determined. The results were compared to EP
scores of tissue sections that were analyzed at the beginning of
the study (nonstored sections).
RNA isolation from FFPE tissue
Total RNA from FFPE tissue sections was extracted by a
silica-coated magnetic bead-based method using VERSANT
Tissue Preparation Reagents (Siemens Healthcare Diagnos-
tics, Tarrytown, USA) as described previously [15, 16]. Iso-
lation was performed manually or automatically (Tissue Prep-
aration System; Siemens Healthcare Diagnostics, Tarrytown,
USA), depending on the amount of tissue sections that were
analyzed within the respective study. DNA-free total RNA
was eluted in 100-μl elution buffer and stored at −80 °C until
use. HBB gene-specific quantitative PCR was performed to
assess contamination of the eluates with residual DNA. Elu-
ates were considered to be substantially free of DNAwhen Cq
values above 38 were detected. In case of DNA contamina-
tion, samples were manually redigested by DNase I treatment.
Assessment of EndoPredict score
EndoPredict tests (Sividon Diagnostics, Cologne, Germany)
were performed as previously described using SuperScript III
PLATINUM One-Step Quantitative RT-PCR System (Life
Technologies, Darmstadt, Germany) and VERSANT kPCR
Molecular System (Siemens Healthcare Diagnostics,
Tarrytown, USA) [13, 14]. In brief, isolated RNA from FFPE
tissue was used to assess expression levels of eight genes of
interest (AZGP1, BIRC5, DHCR7, IL6ST, MGP, RBBP8,
STC2, and UBE2C) and three reference genes (CALM2,
OAZ1, and RPL37A) as well as one gene indicating DNA
presence (HBB) by quantitative RT-PCR (qRT-PCR). PCR
results were uploaded into Web-based software EndoPredict
Report Generator V3.0.2 (Sividon Diagnostics, Cologne, Ger-
many) which calculated the EP score and combined it with the
clinical risk factors tumor size and nodal status to a molecular
clinicopathological risk score, EPclin [1].
Statistics
The relative expression levels of the eight genes of interest and
the EP scores were calculated as described previously [1].
EPclin scores could only be determined for the TCC studies,
because nodal status and tumor size of all other samples were
not available.
In order to analyze the dependency of the EP score from the
TTF and the FT, a reference EP score was calculated based on
test results of samples with assumed standard tissue handling
Fig. 1 Scheme of preanaytical steps from tissue removal to archiving of the FFPE tumor material and related experiments that were performed in this
study
Table 1 Summary of clinical data of tissue samples used for the tumor
cell content study
Number
Tumor cell content 0–20 % 5








Nodal status positive 10
negative 28
unknown 1
ER status (cutoff ≥10 %) positive 39
negative –
PR status (cutoff ≥10 %) positive 31
negative 8
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procedures (10 min at 20 °C prior to fixation and 20 h in
formalin). Precision studies with replicate EndoPredict mea-
surements revealed a total standard deviation of 0.25 EP score
units (1.7 % of the EP score range). To account for the
precision of the EndoPredict test results, a deviation of
±0.75 EP score units from the reference EP score (3-fold
standard deviation of the EP score) was defined as acceptance
limits for all other samples of the TTF and FT studies.
Pearson correlation coefficients (r) were calculated to com-
pare EP test results of paired tissue samples with different
TCC or different storage conditions.
Results
Effect of the time to fixation
In order to study the impact of the TTF, a breast tumor
specimen was cut into several pieces which were stored for
up to 24 h prior to fixation at different temperatures. The gene
expression levels of the reference gene RPL37Awere used as
surrogate marker for the mRNA yield of the individual sam-
ples. Three replicate PCR measurements were performed for
each FFPE tissue section. Mean Cq values of RPL37A were
calculated based on the results of the two sections per tissue
piece. The mean Cq values of RPL37Avaried slightly for each
tumor piece, but no trendwas observed that could be related to
the TTF (Table 2). EP scores of all measurements were com-
pared to the mean EP score obtained from tissue sections that
had been stored for 10 min at 20 °C prior to fixation (reference
conditions). EP scores of all but one sample were within the
reference EP score interval generated at reference conditions
(Fig. 2). The mean deviation of these samples was 0.37 EP
score units (range −0.50 to 0.70). Only the specimen with a
storage time of 24 h at 20 °C before fixation showed a
remarkable decrease in the EP score. The deviation compared
to the reference score was 1.8 EP score units. The risk classi-
fication by EndoPredict was identical for all specimens with a
TTF of up to 12 h, irrespective of the storage temperature.
Even a storage time of 24 h at 4 °C before fixation did not
influence the risk classification.
Impact of the fixation time
In order to investigate the effect of the FT on the EP score, a
fresh tumor was cut into pieces which were incubated in
formalin for up to 10 days. The RNA yield varied slightly
for individual tissue pieces, but no trend was observed that
could be related to the FT (Table 2). Mean EP score of tissue
sections that had been fixed for 20 h was used as reference
score (±3 standard deviations). EP scores of all specimens
with FT from 1 h to 5 days were within the reference interval
with a mean deviation of −0.02 EP score units from the
reference EP score (range −0.40 to 0.40) (Fig. 3). A significant
decrease in the EP score was only detected for tissue sections
that had been fixed for 10 days. In this case, the EP score was
1.2 units lower compared to the reference score. Thus, neither
Table 2 Mean Cq values of the reference gene RPL37A of TTF and FT
samples
Mean Cq RPL37A Standard deviation
TTF
10 min/20 °C 22.47 0.14
10 min/37 °C 21.69 0.05
1 h/4 °C 22.30 0.33
1 h/20 °C 22.26 0.12
12 h/4 °C 22.08 0.12
12 h/20 °C 21.45 0.06
12 h/37 °C 23.61 0.05
24 h/4 °C 20.10 0.12
24 h/20 °C 21.41 0.61
FT
1 h 20.02 0.19
6 h 28.04 0.47
20 h 20.19 0.12
2 days 20.86 0.05
5 days 22.17 0.15

































Fig. 2 EndoPredict test results achieved after different storage times and
temperatures before fixation. The solid line represents the reference score
whichwas derived from themean EP score of the tissue sections that have
been stored for 10 min at 20 °C before fixation.Dotted lines represent the
reference score ±3× its standard deviation as determined by precision
study [24]. Measurements were performed in duplicate (n=2). Mean
values are presented, with standard errors of the means indicated by bars
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a short FT of only 1 h nor longer FTs of up to 5 days affected
the test results of the EndoPredict assay.
Impact of the tumor cell content
RNAwas isolated from whole tissue sections with different
TCC and corresponding tumor-enriched sections with
100 % TCC. Relative expression levels of the eight genes
of interest (AZGP1, BIRC5, DHCR7, IL6ST, MGP, RBBP8,
STC2, and UBE2C) were compared between paired whole
tissue sections and tumor-enriched specimens. Pearson
correlation coefficients ranging from 0.90 to 0.98 demon-
strate significant correlation of expression levels of the
individual EndoPredict genes in tissue sections of different
TCC (Table 3).
EP scores of whole tissue sections and tumor-enriched
samples showed a good correlation with a Pearson correlation
coefficient of 0.97 (Fig. 4a). The mean deviation between
whole and microdissected samples was −0.31 (range −1.70
to 1.10) EP score units. Similar results were obtained when
considering only samples with a TCC of 30 to 100 % as
recommended in the EndoPredict manual (79 % of all sam-
ples). In this case, the Pearson correlation coefficient was 0.98
with a mean deviation of −0.30 EP score units (range −1.70 to
1.10). EPclin scores were also highly correlated (r=0.98)
showing a mean deviation of −0.10 EPclin score units (range
−0.50 to 0.30) (Fig. 4b).
The risk classification based on the EP score showed an
overall agreement of 87 %. Five tumor samples that showed a
disagreement between whole and manually microdissected
sections had an EP score that was close to the cutoff level.
Risk classification based on the EPclin score was identical for
all but two tested samples (concordance of 95 %).
Impact of the section storage time
FFPE tissue sections of 10 breast tumors were stored for
12 months at +4 °C or for 12 months at +20 °C. Cq values
of the reference gene RPL37A increased on average by 0.7 Cq
values for sections stored at 4 °C and 0.9 Cq values for
sections stored at +20 °C when compared to results of
nonstored tissue sections indicating a decrease of RNA yield
over time. Relative expression levels of individual genes,
however, remained constant (Table 4). The Pearson correla-
tion coefficient was >0.99 when comparing EP scores of
samples processed without prior storage and samples stored
at +4 °C (Fig. 5). It was 0.99 when doing the respective
comparison between samples processed immediately and
samples stored at +20 °C. Mean deviation between stored
and nonstored sections was 0.02 (range −0.50 to 0.30) EP
score units for storage at +4 °C and 0.04 (range −0.80 to 0.50)
EP score units for storage at +20 °C. The risk classification by
EndoPredict was identical for stored and nonstored sections
for either condition (concordance of 100 %). Taken together,
these results suggest that the discussed storage conditions
have no significant impact on the EndoPredict score.
Discussion
Invariance to tissue handling and preanalytics is a crucial
requirement for RNA-based diagnostic tests. In this study,
we have systematically evaluated the impact of variations of
different steps in tissue handling including the TTF, the FT,
and the time of FFPE tissue section storage as well as varia-
tions of the TCC on the breast cancer prognosis test
















Fig. 3 EndoPredict test results achieved after different fixation times.
The solid line represents the reference score which was derived from the
mean EP score of the tissue sections that have been fixed for 20 h in
neutral buffered formalin. Dotted lines represent the reference score ±3×
its standard deviation as determined by precision study [24]. Measure-
ments were performed in duplicate (n=2). Mean values are presented,
with standard errors of the means indicated by bars
Table 3 Correlation of
the relative expression
values of the
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to be reasonably expected in the molecular pathology labora-
tory do not have a negative impact on the EndoPredict result.
To our knowledge, this is the first report on the influence of
TTF and FT on the results of a commercially available prog-
nostic breast cancer gene expression test.
It is generally believed that a prolonged time prior to
fixation results in a time-dependent, autolysis-induced RNA
degradation that starts early upon surgical removal of the
tissue [17]. Although pre-FTs should thus be kept as brief as
possible, delays might occur due to transportation from the
surgical room to the pathology laboratory, grossing of the
specimen, or evaluation of frozen sections. It is therefore
important to understand if a prolonged time period prior to
fixation influences RNAyield and the EndoPredict test results.
Our data indicate that a delay in fixation of up to 24 h has no
effect on the RNA yield as demonstrated by mean Cq values
of the reference gene RPL37A. The minor variations between
the mean RPL37A Cq values are most likely caused by
different sizes of the tissue pieces used. These data are in
accordance with previous findings demonstrating that the
RNA yield remains relatively stable in samples incubated at
4 or 25 °C for up to 24 h prior to fixation [18]. Similar results
were also obtained by Godfrey and colleagues who used liver
specimen from a single patient and analyzed the effect of pre-
FTs on the amplification of different sized PCR amplicons of
ß-actin mRNA. No differences were observed between RNA
of immediately fixed specimen and samples with a pre-FT of
12 h for amplicon sizes less than 131 base pairs [19]. On the
other hand, there are other studies that showed decreasing
gene expression levels with a prolonged TTF [20]. Therefore,
the effect of TTF on gene expression seems to be gene-
specific and cannot be generalized. This has also been dem-
onstrated by De Cecco et al. [21] who analyzed RNA isolated
from subdivided breast tumors that were kept at room temper-
ature for up to 24 h prior to freezing. Subsequent analysis was
conducted with cDNA arrays containing 17.172 unique
clones. The authors found that the expression of 2.88 % of
genes was impacted by tissue processing times. Since some of
these genes are described to play a biological role in breast
cancer (e.g., ESR1 and ERBB2), De Cecco et al. assumed that
breast cancer signatures as well as prognostic tests could be
affected by prolonged ischemic times [21]. As shown in this
study, the EndoPredict test tolerates a prolonged TTF of up to
12 h. It appears that the genes included in the EndoPredict are
not modulated by TTF, as are 97 % of the genes studied by De
Cecco et al. The tolerance of the EndoPredict to TTF might
reflect the fact that the EndoPredict assay works on highly
fragmented FFPE RNA. Müller et al. found in a study with
167 FFPE breast carcinoma samples that more than 98 % of
samples had RNA fragment lengths between 150 and 242
bases [22]. The PCR amplicons of the EndoPredict genes of































































Fig. 4 Correlation between the EP (a) and EPclin (b) scores of paired
whole and tumor-enriched, manually microdissected tissue sections from
ER+/HER2− breast cancer patients (n=39). Pearson correlation coeffi-
cient of EP scores was 0.97 with a concordance of EndoPredict risk
classification of 87 %. Pearson correlation coefficient of EPclin scores
was 0.98 with a concordance of EndoPredict risk classification of 95 %.
Black filled circles represent tissue samples with TCC ≥30 %, open
circles tissue sections with TCC <30 %
Table 4 Mean difference of relative expression values (delta Cq value
[nonstored]-delta Cq value [stored]) of the EndoPredict genes of interest
between nonstored and stored FFPE tissue sections
Gene name Mean differences
(nonstored vs 4 °C storage)
Mean differences
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68 to 157 base pairs. Another explanation for the robust
expression of the EndoPredict genes could be that the final
selection of the genes and the training of the algorithm were
done using FFPE tissue samples from routine diagnostics [1]
which presumably have had varying pre-FTs. One can there-
fore assume that genes, which are highly affected by
prolonged pre-FTs, were already ruled out during the devel-
opment of the EndoPredict test.
In a clinical setting, pre-FTs are generally kept at a mini-
mum, and time periods of 12 h at room temperature or 24 h at
+4 °C before fixation are beyond standard variations. The EP
score should therefore not be affected by the TTF encountered
in routine clinical practice.
Similar to the TTF, the FT can greatly vary dependent on
the day time of the surgery or due to a delay in processing over
weekends or holidays. Studies have shown that prolonged FTs
result in poor RNA quality and decreased RNA yields. Con-
sequently, expression level variations caused by strand break-
age and protein-RNA cross-links have been observed [18, 23].
Shorter FTs had similar effects on the RNA quality. Incom-
plete fixation leading to tissue autolysis and inadequate dehy-
dration might be among the reasons for the observed effects
[18]. The analysis of the effect of FT on the EndoPredict test
results in the present study contrasts these findings. EP scores
of tissue pieces fixed for 1 h to 5 days remained stable with
minor variations that were within 3-fold standard deviation of
the EndoPredict score [24]. Detrimental effects were only
detected after 10 days of fixation resulting in a decrease of
the EP score by 1.2 units. Also, the expression levels of the
reference gene RPL37Awhich were used as surrogate markers
for the mRNA yield did not show any systematic decrease in
PCR product as a function of FT. The increased mean Cq
value of the sample with a FT of 6 h seems to be an outlier
most likely caused by different tissue sizes since all other
samples show comparable Cq values with marginal variances.
Similar observations were made by Macabeo-Ong and
Abrahamsen et al. who analyzed gene expression variations
in relation to the FTs. Both studies showed that all or at least
part of the analyzed genes showed stable expression levels
after several days of fixation [20, 23]. Possible explanations
for the robustness of the EndoPredict with regard to FT might
also be the amplicon sizes and the development of the algo-
rithm as explained above. Although our data is limited due to
the small number of tumor samples, the results indicate that
the mRNA of genes included in the EndoPredict test tolerates
prolonged formalin fixation, similar to genes analyzed by
Macabeo-Ong and colleagues. Moreover, our data show that
a prolonged fixation of up to 5 days due to workflow varia-
tions caused by weekends or holidays does not affect
EndoPredict test results.
Tumor tissue and tumor-adjacent normal breast tissue can
have markedly different expression levels for individual
genes. Therefore, it is reasonable that the TCC can have an
impact on gene expression analysis [9, 25]. Like other breast
cancer prognosis tests, EndoPredict requires a specific TCC
range that must be adhered to obtain reliable results [13, 14].
For EndoPredict, this TCC range is 30 to 100 %. Our data
demonstrate a good correlation of EP scores derived from
whole tissue sections with TCC of 30–100 % and EP scores
of consecutive, manually microdissected sections (TCC of
approximately 100 %). Interestingly, even the tissue sections
with a TCC of less than 30 % and the corresponding micro-
dissected tissue samples showed comparable EP scores with a
Pearson correlation coefficient of 0.91. Although the coeffi-
cient was lower compared to samples with a TCC of ≥30 %, it
still indicates substantial equivalency. This indicates that the
relative gene expression of the analyzed genes is even pre-
served in samples with a TCC below 30 %. Similar results
were obtained by Tramm and colleagues who showed that the
surrounding non-neoplastic tissue does not affect the quanti-
fication of ESR1, PGR, and ERBB2 mRNA expression in
breast tumor samples [26]. The test results of the PAM50-
based Prosigna breast cancer prognosis test, however, are
























































EP score - non-stored  section
bFig. 5 Correlation of EP scores
between stored and nonstored
FFPE tissue sections. EP scores
have been determined at the
beginning of the study, after
12 months at +4 °C (a) or after
12 months at +20 °C (b),
respectively. Pearson correlation
coefficients were 0.99 and >0.99
with a concordance of
EndoPredict risk classification of
100 %
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in subtype classification or a negatively biased estimation of a
patient’s risk of recurrence [27]. Accordingly, the manufac-
turer of Prosigna recommends to always remove the surround-
ing non-neoplastic breast tissue. It therefore seems that the
effect of the TCC is gene-specific and needs to be evaluated
specifically for each gene expression test.
Although this study analyzes a moderate number of tumor
samples, the data indicates that the TCC is not an essential
aspect for EndoPredict analysis. Nevertheless, to positively
exclude any detrimental influence of low TCC, the require-
ment for EndoPredict is a minimal TCC of 30 % in the FFPE
tissue section. In cases of lower TCC, a manual microdissec-
tion is recommended.
It has previously been demonstrated that reliable mRNA-
based assessment of ER, PgR, and HER2 status is possible in
up to 21-year-old FFPE samples [22]. Studies on FFPE tissue
blocks showed an increase in fragmentation of RNA with
longer storage times and increased temperature [28, 29]. Ab-
solute expression levels as determined by qRT-PCR were
affected by longer storage times, whereas relative expression
levels remained constant [28]. In contrast, only limited infor-
mation is available if extended storage times of FFPE tissue
sections impact RNA quality. In this study, we could show that
a storage time of FFPE tissue sections of up to 12 months at +
4 °C or at room temperature had no influence on the
EndoPredict test results. A marginal decrease of RNA yield
was observed after storage at +20 °C; relative expression
levels of genes of interest and EP scores, however, remained
constant. Our data on EndoPredict genes is in line with the
previous finding of another group showing that the storage
time of FFPE tissue had only minor effects on relative gene
expression values [28]. Moreover, our data demonstrate that
reliable EndoPredict results can be achieved even if the tissue
sections have been stored for several months after surgery.
In conclusion, our data indicates that variations in tissue
handling which might occur during routine clinical proce-
dures have negligible effects on the results of the
EndoPredict test. This corroborates the statement that the
EndoPredict is a robust test which can be reliably per-
formed in an environment and workflow of a routine mo-
lecular pathological laboratory.
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